Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 11/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.42 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.42 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19569439 | 0.91 | ATF4 (0.42) | ATF4FFAR1PPARGPPARD | |
| SCHEMBL20973933 | 0.90 | ATF4 (0.60) | ATF4 | |
| SCHEMBL19569443 | 0.87 | ATF4 (0.60) | ATF4 | |
| SCHEMBL20999624 | 0.85 | FFAR1 (0.41) | ATF4FFAR1PPARGPPARDSMN1; SMN2 | |
| SCHEMBL19569304 | 0.83 | ATF4 (0.49) | ATF4 | |
| SCHEMBL19555299 | 0.82 | ATF4 (0.53) | ATF4 | |
| SCHEMBL19569436 | 0.81 | ATF4 (0.56) | ATF4FFAR1PPARGPPARD | |
| SCHEMBL19569440 | 0.79 | ATF4 (0.52) | ATF4 | |
| SCHEMBL20999266 | 0.78 | ATF4 (0.48) | ATF4 | |
| SCHEMBL19569258 | 0.78 | ATF4 (0.65) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144440-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2019-05-16 | — | — | US | disclosed |
| WO-2017193034-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144440-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885FFAR1 1632/4885PPARG 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.